EU Approves Troubled Abbott-Alere Deal – But Abbott Still Wants Out

The European Commission has approved Abbott Laboratories' pending acquisition of Alere, on condition that Alere's Epoc, Triage and BNP businesses are divested to alleviate anti-trust concerns. However, Abbott is still looking to cut loose from the $5.8bn deal.

Abbott Laboratories Inc. is standing firm on its decision to kill its proposed acquisition of Alere Inc. despite the European Commission having granted clearance to the dealon Jan. 25.

The company insisted news of the EU approval did not signal reconciliation between the two but was simply a case of going through the motions

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Deals

More from Business